AstraZeneca announced on March 21 that it would invest $2.5 billion to establish its sixth global strategic research and development center in Beijing. The investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic and Technological Development Zone Management Committee, and includes agreements signed with three biotechnology companies (Harbour Biopharma, Syneron Bio and Kangtai Biological).